In this context, treatment of HNSCC patients with antibody agonists of GITR or OX40 could provide a powerful tool to diminish the suppressive potential of intratumoral Treg and enhance anti-tumor immunity. This evidence concerns the gene TNFRSF18 and neoplasm.